

SPARC/Sec/SE/2026-27/20

July 13, 2026

To,

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations, we wish to inform you, the Board of Directors of the Company has considered and approved the following:

1. Dr. Rajamannar Thennati (DIN: 001415412) retires from the Board of Directors of the Company upon completion of his term as a Director at the ensuing 21st Annual General Meeting i.e., August 10, 2026.
2. Appointment of Mr. Anil Raghavan (DIN: 03548731), Chief Executive Officer (CEO) of the Company as Managing Director and Chief Executive Officer of the Company with effect from August 11, 2026 and liable to retire by rotation, subject to the approval of members at the ensuing 21st Annual General Meeting of the Company.

Mr. Anil Raghavan is not related to any other director of the Company and is not debarred from holding the office of director by any SEBI order or any other authority

Details required under Regulation 30 read with Para A of Schedule III (Part A) of SEBI Listing Regulations, along with the additional details required pursuant to SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as **Annexure - A.**

You are requested to take the above information on record.

For Sun Pharma Advanced Research Company Limited

Kajal Damania
Company Secretary and Compliance Officer

Encl: As above

Annexure A

Disclosures required under Regulation 30 read with Para A of Schedule III (Part A) of SEBI Listing Regulations, along with the additional details required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. No	Particulars	Details of Senior Management Personnel	
		Mr. Anil Raghavan	Dr. Rajamannar Thennati
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment	Retirement
2	Date of appointment/ re-appointment / cessation (as applicable) & term of appointment/re-appointment	August 11, 2026	August 10, 2026
3	Brief profile (in case of appointment)	Mr. Anil Raghavan currently serves as the Chief Executive Officer of Sun Pharma Advanced Research Company Limited (SPARC). Anil is responsible for developing and executing strategies to realize SPARC's vision of becoming a Global Pharmaceutical Leader with a portfolio of innovative solutions. He operates from SPARC's Mumbai office. Mr. Anil also serves as a mentor of an early stage Machine Learning company, AIRAMATRIX Private Limited which focuses on the application of high content image processing and deep learning to transform drug development and clinical practice. Anil spent a decade consulting with leading firms such as Arthur Andersen, KPMG and Cambridge	Not Applicable

		Technology Partners before joining Quintiles. He helped the leadership teams of several companies in developing and evaluating business strategy, and improving business performance. Anil served customers in varied segments like Media and Entertainment, Telecommunications, Health Care services, and Technology/Outsourcing. Anil substantially contributed to developing consulting solutions for the emerging Information Technology and Business Process Outsourcing industries. Anil is an Industrial Engineer with a deep interest in evolving science and technologies in pharmaceutical R&D and health care delivery segments. An active speaker at events, he has participated in several industry sector studies, working with business lobbies and industry associations to highlight sectoral opportunities and challenges.	
4	Disclosure of Relationship between Directors (in case of appointment of a Director)	Mr. Anil Raghavan is not related to any director of the Company.	Not Applicable

For Sun Pharma Advanced Research Company Limited

Kajal Damania
Company Secretary and Compliance Officer

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusr 391775, District: Vadodara, Gujarat, India.